WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Efocipegtrutide

Governed registry record

3 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.

    DOI: 10.1016/j.cct.2023.107176PMID: 37028504

    Source identity and connection checked by Codex (AI).

  2. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.

    DOI: 10.4330/wjc.v17.i8.107991

    Source identity and connection checked by Codex (AI).

  3. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

    DOI: 10.1016/j.peptides.2025.171380PMID: 40081498

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Bailey CJ
  • Flatt PR
  • Conlon JM
  • Abdelmalek MF
  • Suzuki A
  • Sanchez W
  • Lawitz E
  • Filozof C
  • Cho H
  • Baek E
  • Choi J
  • Baek S
  • Bhat S
  • Fernandez CJ
  • Lakshmi V
  • Pappachan JM